Drug intelligence / Profile preview

JNJ-53718678 + JNJ-64417184

Development stage
Phase 1
Lead developer
Janssen Research & Development
Modality
Small Molecules
Administration
Oral
01

Overview

JNJ-53718678 + JNJ-64417184 is an **oral combination of two investigational small molecules** being developed for the treatment of **respiratory syncytial virus (RSV) infection**. JNJ-53718678 is a **fusion inhibitor**, which blocks the fusion of the virus with host cell membranes, inhibiting viral entry and propagation. JNJ-64417184 is a **viral polymerase inhibitor**, targeting the production of viral proteins and thereby blocking replication. Both compounds have demonstrated activity against RSV by different mechanisms, and combination therapy is hypothesized to improve antiviral efficacy by targeting two essential steps in the viral life cycle. Both drugs are in early-phase clinical trials and have been primarily studied by Janssen (Johnson & Johnson companies)[1][3][4][7][10].

Other names
JNJ-8678 + JNJ-64417184
02

Targets

RSV F (Respiratory syncytial virus fusion protein)RSV L (Respiratory syncytial virus L protein)

Beyond the preview

Go deeper on JNJ-53718678 + JNJ-64417184.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-53718678 + JNJ-64417184.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call